雷贝拉唑联合莫沙必利治疗反流性食管炎疗效观察

目的探讨雷贝拉唑联合莫沙必利治疗反流性食管炎（reflux esophagitis,RE）的临床疗效和安全性。方法将120例经胃镜证实的反流性食管炎患者随机分成治疗组和对照组。治疗组60例：口服雷贝拉唑10mg,1次/d,莫沙必利5mg,3次/d;对照组60例：口服奥美拉唑20mg,2次/d,莫沙必利5mg,3次/d。疗程均为6周,疗程结束后复查胃镜,观察镜下愈合率,并记录症状改善情况及不良反应。结果治疗1周后,治疗组和对照组临床症状改善总有效率分别为75%,46.7%,两组比较有显著性差异（P〈0.01）;6周后,治疗组和对照组临床症状改善总有效率、胃镜下有效率分别为95%,90%、93.3%,90%。两组差异均无统计学意义（P〉0.05）。结论雷贝拉唑联合莫沙必利治疗反流性食管炎症状改善迅速,病变愈合率和症状改善率高,是治疗反流性食管炎安全、有效、理想的药物。

Clinical efficacy of rabeprazole combined with mosapride in the treatment of reflux esophagitis

Objective To investigate the efficacy and safety of rabeprazole and mosapride in the treatment of reflux esophagitis. Methods 120 patients with reflux esophagitis proven by endoscope were randomly divided into two groups ： The treatment group （ n = 60） received rabeprazole 10 mg once daily and mosapride 5 mg three times daily ; The control group （ n = 60 ） received omeprazole 20 mg twice daily and mosapride 5 mg three times daily. After 6 weeks, endoscopy was performed to study the healing rate, Improvement in symptoms and adverse effects were recorded. Results After 1 week,the total symptom improvement rates in the treatment group and the control group were 75% ,46. 7% , There were significant differences between the two groups （P 〈 0. 01 ） ; After 6 weeks, the total symptom improvement rates and the endoscopic healing rates were 95% ,90%. 93.3% ,90% respectively, There were no statistically significant differences between the two groups（ P 〉 0. 05 ）. Conclusion Rabeprazole combined with mosapride can rapidly improve the symptom of RE and is safe and effective in the treatment of reflux esophagitis.